Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7017773 Receptor Occupancy Study
NCT03507569Phase 1Completed
- Sponsor
- Roche
- Start
- Apr 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alogabat in Autism Spectrum Disorder (ASD), sponsored by Roche. Primary endpoints: Percentage of Brain Alpha5-Containing GABA-A Receptors Occupied by RO7017773 and Plasma Concentrations of RO7017773. Started Apr 2018; status: completed.
02
Drugs
alogabat
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03507569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03507569.